KVUE changes
Pick any two versions below to diff them.
- Price
- $18.62 → $19.31(+3.7%)
- Next earnings
- Nov 6, 2026 → Jan 30, 2027
- Risks
- The Kenvue price follows the Kimberly-Clark share price through the fixed exchange ratio. A fall in Kimberly-Clark shares lowers the value that Kenvue holders receive. After the closing, holders own about 46% of a combined company that must complete a large integration. The deal still needs some foreign regulatory approvals and other closing conditions. A delay or a failure of the deal returns the price to Kenvue's standalone value, which includes the Tylenol litigation and slow growth. Lawsuits claim that the use of acetaminophen (Tylenol) during pregnancy is associated with autism and ADHD. A US federal court entered judgment for the sellers in February 2024. In October 2025, the State of Texas sued Kenvue, and most claims were dismissed in November 2025, but Texas filed an appeal in December 2025. Kenvue keeps the liability for talc products sold outside the US and Canada. Group claims about Johnson's Baby Powder started in Australia in February 2026 and in Scotland in March 2026, and Kenvue cannot yet estimate the possible cost. Organic sales growth was only 0.7% in Q1 removed: 2026 and added: 2026, 1.6% in Q2 added: 2026 and 2.9% in Q3 2026. Inflation and tariffs lowered the gross margin in Q2 2026.
- Checkpoints
- removed: Nov 6, 2026 (estimate): added: Oct 30, 2026: Q3 2026 results: organic sales growth. removed: Pending. added: Passed. Watch: Positive organic sales growth and a stable adjusted operating margin pass; a return to falling sales fails. added: Outcome: Organic sales grew 2.9%, the fourth quarter of growth in a row, and the adjusted operating margin rose to 21.9% from 21.5%. Q4 2026 (estimate): Closing of the Kimberly-Clark acquisition. Pending. Watch: The deal closes in the fourth quarter of 2026 on the agreed terms; a new delay past 2026 or a failed regulatory approval fails. 2027 (estimate): Combined company: cost savings and Kimberly-Clark share price. Pending. Watch: Kimberly-Clark reports cost savings on plan and its shares rise after the closing; integration problems or a lower share price fail.
- Recent events
- Oct added: 30, 2026: Kenvue reported Q3 2026 results. Net sales rose 3.2%, and organic sales rose 2.9%, with volume up 1.6%. This was the fourth quarter of growth in a row. Diluted EPS was $0.22, and adjusted EPS was $0.29, up 4%. The adjusted operating margin rose to 21.9% from 21.5%, helped by productivity savings and US tariff refunds. Kenvue gave no guidance because of the pending Kimberly-Clark deal. Oct 13, 2026: The European Commission cleared Kimberly-Clark's purchase of Kenvue on the condition that Kimberly-Clark sells its feminine care business in the European Economic Area, including Kotex, Lidie, Camelia and Record, to Dilek Gida Uretim of Turkey. On the same day, Kimberly-Clark said that Kenvue noteholders gave enough consents to amend the Kenvue indenture in its exchange offer, which expires on October 27, 2026. Oct 9, 2026: Kenvue signed a supplemental indenture that removes most covenants of its senior notes. The changes take effect when Kimberly-Clark's exchange offer for the notes settles, at about the closing of the acquisition. Aug 6, 2026: Kenvue reported Q2 2026 results. Net sales rose 3.0%, and organic sales rose 1.6%, the third quarter of growth in a row. Diluted EPS was $0.24, and adjusted EPS was $0.31, up 7%. The adjusted operating margin fell to 22.1% from 22.7% because of inflation, tariffs and higher brand support. Kenvue gave no guidance because of the pending deal, and it said that it works to close the deal in the fourth quarter of 2026. May 12, 2026: CFO Amit Banati left the company, as announced in February 2026. Chief Accounting Officer Heather Howlett became interim CFO. May 7, 2026: Kenvue reported Q1 2026 results. Net sales rose 4.5%, and organic sales rose 0.7%. Diluted EPS was $0.25, up 47%, and adjusted EPS was $0.32, up 33%.